Abstract

Osteoarthritis (OA）is a common orthopaedic disease in middle-aged and aged people. To date, no disease-modifying drug is available to prevent the progression of OA. Surgical treatment of OA has complications such as pain and high costs with increased risk of post-operative infections. An intra-articular drug delivery is a conservative treatment method to apply therapeutic composites directly into the OA joint cavity. This method has an advantage to improve the bioavailability of therapeutics and hence is a widely preferred choice to test novel disease-modifying drug targets for OA. Herein, we summarised and discussed the current status of intra-articular therapy for OA treatment as well as outlined drug delivery of small molecular, protein and gene delivery for OA therapy. Currently, new targeted nano-based drug delivery systems, including nanoparticles, exosomes and hydrogel formulations under investigation for OA treatment via intra-articular injection are also addressed. The emerging trend demonstrates that intra-articular drug delivery has vast prospects for the clinical selective treatment of OA. The rational application of intra-articular injection of drugs and biological agents will be of great significance for alleviating the patients with OA, improving their quality of life, delaying surgery, and reducing the disease burden of OA.

摘要

骨关节炎(Osteoarthritis, OA)是中老年人常见的骨科疾病，目前尚无改善病情的药物来阻止OA的进展。术后感染。关节内给药是一种保守的治疗方法，可将治疗复合物直接应用到 OA 关节腔中。这种方法具有提高治疗剂生物利用度的优势，因此是测试新疾病的广泛首选。 OA治疗药物靶点修饰。在此，我们总结和讨论了OA治疗关节内治疗的现状，概述了OA治疗的小分子、蛋白质和基因递送药物递送。目前，新的靶向纳米药物递送系统，包括正在研究用于 OA 治疗的纳米颗粒、外泌体和水凝胶制剂还解决了通过关节内注射的问题。这一新兴趋势表明，关节内给药对于 OA 的临床选择性治疗具有广阔的前景。合理应用关节腔内注射药物和生物制剂，对于缓解OA患者的病情、提高其生活质量、延缓手术、减轻OA疾病负担具有重要意义。